Table 2.
Characteristics and findings of included studies
| Care Location | Year | Country | Design | Intervention | Comparator | Number of participants | Uptake (%) | SVR (%) |
|---|---|---|---|---|---|---|---|---|
| Primary Care | ||||||||
| Bloom | 2017 | Australia | Prospective cohort study of treatment uptake and SVR | Adherence to DAA treatment protocols | Treatment by tertiary care provider | 1044 | 503 (40.6) | 253 (50.2) |
| Francheville | 2017 | Canada | Prospective observational study design | Specialist nurse-led care | No comparator group | 242 | 93 (38.4) | 82 (88.2) |
| Kattakuzhy | 2017 | USA | Non-randomised open label study | Treatment by primary care providers (PCP) and nurse practitioners (NP) | Standard care - Treatment by secondary care clinic | NP 150 PCP 160 | NP 134 (89.3) PCP139(86.9) | |
| McCLure | 2017 | Australia | Retrospective data analysis of SVR12 | Nurse-led care and GP remote consultation | Specialist care in Tertiary centre | Nurse-led 70 | 50 (74.3) | 46 (65.7) |
| Miller | 2016 | USA | Retrospective observational study | Treatment by primary care providers | No comparator group | 95 | 79 (83) | |
| Norton | 2017 | USA | Retrospective cohort study of SVR | Treatment in urban primary care centre | SVR 12 in PWIDs and non_PWIDs | 89 | 85(95.5) | |
| Wade | 2018 | Australia | Randomised controlled trial | Testing, assessment and treatment in primary care | Testing, assessment and treatment in tertiary care | 59 | 31 (52.5) | 14 (23.7) |
| Integrated Health Systems (ECHO) | ||||||||
| Abdulameer | 2016 | USA | Retrospective data analysis of SVR 12 | VA-Echo model supporting primary care providers | No comparator group | 588 | 318 (54) | |
| Beste | 2017 | USA | Retrospective cohort study of treatment uptake and SVR | VA-Echo model supporting primary care providers | Standard care - Treatment by unexposed primary care providers | 6431 | 1303 (21.4) | (58.2) |
| Buchanan | 2015 | United Kingdom | Retrospective data analysis | Community-based outreach clinic | Standard care - Treatment by secondary care clinic | 77 | 24 (31.2) | |
| Georgie | 2016 | USA | Retrospective data analysis of SVR12 | VA-Echo model supporting primary care providers | Treatment by sub-specialist providers | 623 | Genotype 1 (GT1) (99) GT2 (98) GT3 (79) | |
| Opioid Treatment Centres | ||||||||
| Butner | 2017 | USA | Retrospective data analysis | Opioid treatment programme | No comparator group | 75 | 75.0 | 64 (85.0) |
| Morris | 2017 | Australia | Retrospective data analysis of treatment uptake and SVR | Treatment in a community-based harm reduction and treatment facility | No comparator group | 127 | 122 (96) | 102 (80.3) |
| Read | 2017 | Australia | Retrospective data analysis of SVR12 | Treatment of PWIDs in primary care setting | No comparator group | 72 | 59 (81.9) | |
| Pharmacies / Pharmacist Clinics | ||||||||
| David | 2017 | USA | Retrospective data analysis of SVR12 | Pharmacy-managed clinics | Treatment by non-pharmacist providers | 204 | (83.6) | |
| Radley | 2017 | United Kingdom | Pilot cluster RCT of treatment uptake and SVR | Treatment in community Pharmacy | Treatment by secondary care clinic | 26 | 3 (11.5) | 3 (11.5) |
| Telemedicine | ||||||||
| Cooper | 2017 | Canada | Retrospective cohort study of treatment uptake and SVR | Use of telemedicine | Treatment by secondary care clinic | 157 | 35.0 | 18 (11.5) |